Jagsonpal Pharmaceuticals has entered into a business transfer agreement (BTA) with Group Pharmaceuticals to acquire its wellness portfolio on a going-concern basis through a slump sale.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.